LRP5 facilitates tumorigenesis as a co-receptor that initiates WNT/β-catenin activation,60 which enhances the maintenance of cancer stem cells.61 Our results demonstrate that LRP5 and β-catenin are markedly downregulated in butyrate-treated cells. The gene discussed is LRP5; the disease is cancer.